This complaint is from a literature source.The following literature cite has been reviewed: fakess, s., o' loughlin, m., tolat, a.Left ventricular thrombus following radiofrequency ventricular tachycardia ablation.Heart rhythm case reports 2022;-:1¿4).2022, march 24.Doi:https://doi.Org/10.1016/j.Hrcr.2022.03.013.No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because no lot number was provided by the customer.Manufacturer's ref #: (b)(4).
|
This complaint is from a literature source.The following literature cite has been reviewed: fakess, s., o' loughlin, m., tolat, a.Left ventricular thrombus following radiofrequency ventricular tachycardia ablation.Heart rhythm case reports 2022;-:1¿4).2022, march 24.Doi:https://doi.Org/10.1016/j.Hrcr.2022.03.013.Objective/methods/study data: radiofrequency catheter ablation (rfca) has become a mainstay in the treatment of both atrial and ventricular tachyarrhythmias since first being developed in 1986.Over 235,000 ablation procedures are performed annually, with 7% of procedures being for ventricular tachycardia (vt) or premature ventricular contractions (pvc), a percentage that continues to grow.1 as experience in ablation techniques has grown, associated complications have become less common, but they remain an area of focus as the field advances.Thrombus formation is one such complication commonly associated with rfca, with an incidence of 0.6%¿0.8%, a risk that grows to 2.0% for the ablation of ventricular tachyarrhythmias.2 despite its being a relatively rare complication, the clinical sequelae of thrombus formation can be devastating, prompting a recent resurgence in the study of post-ablation thrombogenesis and treatment.Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: thermocool stsf.Other biosense webster devices that were also used in this study: n/a.Non-biosense webster concomitant devices that were also used in this study: baylis trans-septal needle.Adverse event(s) and provided interventions: a 43-year-old male patient developed a thrombus extending a length of 4.0 x 3.5 cm with a thickness of 0.6 cm post ablation, it was not present on the computed tomography performed prior to the procedure.Following this discovery, the patient was started on apixaban 5 mg twice daily for 1 month.
|